Russell Investments Group Ltd. Raises Position in Medpace Holdings, Inc. $MEDP

Key Points

• Russell Investments Group Ltd. increased its holdings in Medpace Holdings, Inc. by 118.7% during Q1, owning about 0.24% of the company, worth approximately $21 million.
• Medpace reported a $3.10 EPS for the last quarter, surpassing estimates and marking a 14.2% year-over-year revenue growth.
• Insiders, including the CEO, sold shares valued at over $51 million in the last quarter, resulting in a significant decrease in their ownership stakes.

Russell Investments Group Ltd. boosted its stake in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 118.7% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 68,973 shares of the company's stock after purchasing an additional 37,442 shares during the period. Russell Investments Group Ltd. owned about 0.24% of Medpace worth $21,016,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in MEDP. Invesco Ltd. grew its stake in shares of Medpace by 9.4% in the first quarter. Invesco Ltd. now owns 1,186,768 shares of the company's stock valued at $361,596,000 after buying an additional 102,015 shares in the last quarter. Mawer Investment Management Ltd. purchased a new position in Medpace during the 1st quarter valued at about $212,131,000. Bessemer Group Inc. grew its position in Medpace by 1.1% in the 1st quarter. Bessemer Group Inc. now owns 582,269 shares of the company's stock valued at $177,411,000 after acquiring an additional 6,225 shares in the last quarter. AQR Capital Management LLC increased its stake in Medpace by 31.3% during the fourth quarter. AQR Capital Management LLC now owns 480,186 shares of the company's stock worth $159,532,000 after purchasing an additional 114,436 shares during the period. Finally, Epoch Investment Partners Inc. lifted its position in shares of Medpace by 5.3% during the fourth quarter. Epoch Investment Partners Inc. now owns 438,100 shares of the company's stock worth $145,550,000 after purchasing an additional 21,881 shares in the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Medpace news, CEO August J. Troendle sold 48,487 shares of the business's stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $451.69, for a total value of $21,901,093.03. Following the completion of the sale, the chief executive officer owned 962,615 shares in the company, valued at approximately $434,803,569.35. The trade was a 4.80% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, President Jesse J. Geiger sold 41,801 shares of the firm's stock in a transaction that occurred on Thursday, July 24th. The stock was sold at an average price of $453.11, for a total transaction of $18,940,451.11. Following the transaction, the president owned 36,503 shares in the company, valued at approximately $16,539,874.33. This trade represents a 53.38% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 112,788 shares of company stock valued at $51,018,354 in the last 90 days. Company insiders own 20.30% of the company's stock.

Medpace Trading Down 0.2%

NASDAQ:MEDP traded down $0.77 during midday trading on Tuesday, hitting $462.14. 323,418 shares of the company were exchanged, compared to its average volume of 728,171. Medpace Holdings, Inc. has a fifty-two week low of $250.05 and a fifty-two week high of $501.30. The company has a market capitalization of $12.98 billion, a PE ratio of 34.36, a price-to-earnings-growth ratio of 2.91 and a beta of 1.42. The company has a fifty day simple moving average of $369.30 and a 200 day simple moving average of $332.71.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its quarterly earnings data on Monday, July 21st. The company reported $3.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.00 by $0.10. Medpace had a return on equity of 67.66% and a net margin of 18.74%.The company had revenue of $603.31 million for the quarter, compared to analyst estimates of $537.70 million. During the same quarter last year, the company posted $2.75 earnings per share. The business's quarterly revenue was up 14.2% compared to the same quarter last year. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. As a group, equities research analysts expect that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have commented on MEDP. Cowen cut shares of Medpace from a "buy" rating to a "sell" rating in a research report on Wednesday, July 23rd. Robert W. Baird upped their price target on Medpace from $313.00 to $490.00 and gave the stock a "neutral" rating in a report on Wednesday, July 23rd. TD Cowen reaffirmed a "sell" rating and issued a $366.00 price target (up previously from $283.00) on shares of Medpace in a research report on Wednesday, July 23rd. Mizuho boosted their price objective on Medpace from $328.00 to $510.00 and gave the stock an "outperform" rating in a research report on Friday, July 25th. Finally, Truist Financial raised their target price on shares of Medpace from $298.00 to $436.00 and gave the company a "hold" rating in a report on Wednesday, July 23rd. Two investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have given a Sell rating to the company's stock. According to MarketBeat.com, Medpace currently has a consensus rating of "Reduce" and a consensus price target of $406.60.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.